REDX.L Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 bal. 2024 @ 19:28):

Stats
Dzisiejszy wolumen	20.48M
Średni wolumen	838 041
Kapitalizacja rynkowa	58.35M
EPS	£-0.0370 ( Q4 \| 2023-09-30 )
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-1.500 (Sector) 0 (Industry) 0
ATR14	£2.03 (13.52%)

AMYT.L -11.73%

APH.L -0.13%

AVCT.L -0.33%

AZN.L -0.37%

BMK.L 7.59%

BVXP.L -2.16%

C4XD.L 27.32%

CIR.L 0.00%

CLIN.L 0.11%

DEST.L -2.51%

DPH.L 0.05%

EAH.L 3.40%

ERGO.L 0.15%

ETX.L -6.74%

EVG.L 2.25%

FAB.L -1.59%

FARN.L -5.98%

FUM.L 0.27%

GDR.L 1.10%

GNS.L 1.43%

GSK.L -0.49%

HCM.L -0.36%

HEMO.L -2.66%

HIK.L -0.53%

IMM.L -1.15%

INDV.L -0.05%

IXI.L -5.25%

MTPH.L 1 794.74%

MXCT.L -2.17%

N4P.L -4.71%

NCYT.L -2.42%

NFX.L -5.00%

OBD.L 3.33%

OKYO.L -24.32%

ONC.L 0.45%

OPTI.L -3.63%

OVB.L -2.22%

OXB.L 2.58%

PRM.L -4.82%

PRTC.L 0.98%

PYC.L -6.25%

REDX.L 31.58%

RENE.L -2.17%

SAR.L 8.67%

SCLP.L -1.86%

SLN.L -0.93%

SNG.L 3.48%

STX.L 2.70%

TILS.L 8.33%

TRX.L -1.15%

VAL.L 0.00%

VEC.L 0.00%

Wolumen Korelacja

Długi: -0.34 (neutral)

Krótki: 0.93 (very strong)

Signal:(57.69) Expect same movement, but be aware

Redx Pharma PLC Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Redx Pharma PLC Korelacja - Waluta/Towar

0.64
( weak )

0.50
( neutral )

0.66
( moderate )

-0.01
( neutral )

-0.63
( weak negative )

0.11
( neutral )

Redx Pharma PLC Finanse

Annual	2023
Przychody:	£4.20M
Zysk brutto:	£3.24M (77.15 %)
EPS:	£-0.0990

FY	2023
Przychody:	£4.20M
Zysk brutto:	£3.24M (77.15 %)
EPS:	£-0.0990

FY	2022
Przychody:	£18.69M
Zysk brutto:	£18.69M (100.00 %)
EPS:	£-0.0612

FY	2021
Przychody:	£10.04M
Zysk brutto:	£0.00 (0.00 %)
EPS:	£-0.127

Financial Reports:

No articles found.

Redx Pharma PLC Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Redx Pharma PLC

Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating anti-cancer and fibrosis targets in the areas of unmet medical needs. The company also develops RXC004, a porcupine inhibitor that is in Phase II clinical trial for targeted therapy of Wnt-ligand driven cancer; and RXC007, an oral selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor for the treatment of fibrotic diseases. In addition, it develops gastrointestinal targeted ROCK inhibitor to treat crohn's disease-associated fibrosis; discoidin domain receptors (DDRs) inhibitor for the treatment of multiple fibrotic conditions; and RXC006, a porcupine inhibitor targeting fibrotic diseases, including idiopathic pulmonary fibrosis. The company has a research collaboration agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase pathway. Redx Pharma Plc was incorporated in 2010 and is based in Macclesfield, the United Kingdom.